Home » Innovation and beauty » Sucampo present lubiprostone phase 3 trial data in Japanese CIC in DDW 2011 Sucampo Pharmaceuticals.

The purpose of the long-term security trial was a evaluation of quality of life scores at baseline and after treatment. Data describing the results of both trials were the subject of poster #DDW/AGA 1038006, titled Lubiprostone Improves Not Only Spontaneous Bowel Movement But Also Quality of Life in Sufferers with Chronic Idiopathic Constipation: Phase III Randomized, Double-Blind, and Placebo-Controlled Research and Long-Term Treatment Research In Japan, were reported at the annual Digestive Disease Week meeting, kept in Chicago, Illinois, and included these highlights: In the four-week efficacy scientific trial: Patients treated with lubiprostone had a statistically significant differ from baseline at Week 1 in the average number of reported SBMs .And this study simply gives us a fresh level of proof that this thinking is actually correct. Noting it is possible that depression and psoriasis reveal the same pathways, Goldenberg stated the next logical part of psoriasis treatment can be to see if the drugs used to take care of psoriasis also have a direct effect on depression. We might ultimately find out that the same inflammatory mechanisms that contribute to psoriasis also exacerbate a chemical substance imbalance leading to depression risk, he said. The award recognizes UCLA's success and commitment in implementing excellent care for stroke patients, according to evidence-based recommendations. To get the award, UCLA Stroke Middle at Ronald Reagan UCLA Medical Center accomplished an 85 % or more adherence to all Obtain With The Guidelines-Stroke Quality Achievement indicators for two or even more consecutive 12-month intervals and attained 75 % or more compliance with six of 10 Get With The Guidelines-Stroke Quality Measures, which are reporting initiatives to measure quality of caution.